New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

• Main Authors: Nam Ah Kim (Author), Sungyoul Hong (Author), Ki Hyun Kim (Author), Du Hyung Choi (Author), Joo Seok Kim (Author), Kyung Eui Park (Author), Jun Young Choi (Author), Young Kee Shin (Author), Seong Hoon Jeong (Author)
• Format: Book
• Published: MDPI AG, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially degraded by aldehyde oxidase (AO) in human liver...